Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10Prostatic Neoplasms 2Obesity 2Vitamin D Deficiency 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Neurofibromatosis 1 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Helicobacter Infections 1Giant Cell Tumor of Bone 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

Denosumab 3gentamicin-polymethylmethacrylate bead 1fludarabine 1aldesleukin 1Zoledronic Acid 1Vitamin D 1Nivolumab 1Ipilimumab 1Dasatinib 1Cyclophosphamide 1Calcium 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Giant Cell Tumor of Bone × Vitamin D × Clear all
NCT00396279 2022-11-08

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
37 enrolled 13 charts

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡